



Impact of statin therapy on late target lesion revascularization after everolimus-eluting stent implantation according to pre-interventional vessel remodeling and vessel size of treated lesion

Kohei Asada¹ · Teruki Takeda² · Yosuke Higo¹ · Yuichi Sawayama¹ · Noriaki Yagi¹ · Megumi Fukuyama¹ · Masayuki Yamaji² · Hiroshi Sakai¹ · Hiroshi Mabuchi² · Takashi Yamamoto^{1,3} · Yoshihisa Nakagawa¹

Received: 21 February 2022 / Accepted: 11 May 2022
© The Author(s) 2022




Fig. 4 Incidence of late TLR in overall study population: **A** positive remodeling group versus negative remodeling group. Incidence of late TLR in **B** positive remodeling group and in **C** negative remodeling group: statin versus non-statin groups. EES, everolimus-eluting stent; TLR, target lesion revascularization




Fig. 5 Incidence of late target lesion revascularization in **A** non-small vessel size lesions and **B** in small vessel size lesions: statin versus non-statin groups. In statin group, incidence of late target lesion revascularization according to follow-up low-density lipoprotein cho-

lesterol (LDL-C) level in **C** non-small vessel size lesions and in **D** small vessel size lesions: follow-up LDL-C ≥ 100 versus < 100 mg/dL. EES everolimus-eluting stent, LDL-C low-density lipoprotein cholesterol